Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIKIDS: Eliglustat With or Without Imiglucerase in Pediatric Gaucher Disease Type 1 and 3
jRCT2080224970Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of eliglustat in Gaucher disease type 1 (GD1) and Gaucher disease type 3 (2 cohorts), sponsored by Sanofi. Primary endpoints: Pharmacokinetics of eliglustat, Safety of eliglustat ± imiglucerase and 1 more. Started Nov 2019; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on jRCT2080224970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224970.